Facebook
Twitter
LinkedIn

Media Center

CLSI Kicks off Partnering Days with JT Pharma
Facebook
Twitter
LinkedIn

Dr. Shigenori Ohkawa, SVP Japan Tobacco and Head of Central Pharmaceutical Research Institute, kicks off CLSI’s JT Pharma Partnering Day on March 5 in San Francisco.

The California Life Sciences Institute (CLSI) kicked off it’s first Partnering event of 2019 with JT Pharma, the Pharmaceutical Division of Japan Tobacco, Inc., on March 5 & 6.  The event brought twenty Bay Area startups together in private meetings with JT Pharma representatives to explore partnering opportunities. The two-day event began with a private presentation by CLSI to JT Pharma representatives on The Bay Area Ecosystem, followed by a public presentation by JT Pharma and a networking reception at STEM Kitchen in Mission Bay San Francisco.

JT Pharma focuses mainly on the fields of metabolic diseases, viral infection and autoimmune / inflammatory diseases. It seeks cutting-edge, innovative science and global development of orally active, small molecule therapeutics, and is looking for partnering opportunities (i.e., research and/or development collaborations), contract research and licensing arrangements with leading academic institutions and pharma / biopharma companies to enhance internal R&D efforts. The company is searching for early-stage, first-in-class, orally active, small molecule NCEs that it can develop into therapeutics, and is also interested in novel, first-in-class drug targets.

Japan Tobacco launched its pharmaceutical business in 1987 with the goal of creating original and innovative drugs for patients suffering from diseases. The company has been steadily expanding, strengthening its R&D capabilities, which is a cornerstone of its pharmaceutical business. In 1993, the company opened its Central Pharmaceutical Research Institute in Osaka and, in 2020, established a clinical development base outside Japan with the addition of a development function to Akros Pharma Inc., JT Pharma’s U.S. subsidiary.